This is the authors' abstract. We don't add key points for this paper.
A novel approach for treatment of type 2 diabetes is based on the gut hormone glucagon-like peptide-1 (GLP- 1), which is antidiabetic due to its combined action to stimulate insulin secretion, increase beta-cell mass, inhibit glucagon secretion, reduce the rate of gastric emptying and induce satiety. A problem is, however, that the peptide is rapidly inactivated by the enzyme dipeptidyl peptidase-4 (DPP-4), resulting in a half-life of active GLP-1 of only approximately 1-2 minutes. To overcome this inconvenient drawback for the treatment of diabetes, two strategies have been successful; one strategy uses DPP-4 resistant GLP-1 receptor agonists whereas the other strategy uses inhibition of DPP-4. Such inhibition will increase the levels of endogenous active GLP-1 and prolong its half-life. The rationale behind the strategy is evident from studies in animals with genetic deletion of DPP-4, which have improved glucose tolerance and increased insulin secretion in response to oral glucose. Furthermore, in experimental animals, different pharmacological DPP-4 inhibitors are antidiabetic. Recently also studies in subjects with type 2 diabetes have shown that prolonged DPP-4 inhibition for up to 1 year is antidiabetogenic because fasting and postprandial glucose as well as HbA1c levels are reduced. This is seen in association with good tolerability and weight neutrality. Hence, DPP-4 inhibition has the potential to be a novel, efficient and tolerable approach to treat type 2 diabetes.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Bo Åhrén (2005) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: